BASE mRNA facility focuses on messenger RNA design, manufacturing, and research. They provide end-to-end research services to design, manufacture, and test new mRNA medicines.

BASE mRNA facility

Base4 Biotechnology focuses on RNA-modulating small molecules and employs a structure-based approach to address RNA targets using their proprietary VERITAS Platform. The platform is AI-enhanced and designed to discover selective molecules against druggable RNA regions.

Base4 Biotechnology

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals focuses on developing therapies using RNA interference technology to target genes associated with diseases, particularly those with significant unmet medical needs. self-described as aiming to have numerous products in clinical trials or on the market by 2025.

Arrowhead Pharmaceuticals

BASE Facility | 2,631 followers on LinkedIn. We make mRNA vaccines and therapies. | BASE is a leader in the manufacture and research of mRNA vaccines and therapies.

We are a leading supplier of mRNA, with end-to-end capabilities for the design, manufacture, and formulation of mRNAs. Our expert team of scientists has experience in building hundreds of mRNA drugs for a wide range of applications.

Experienced research professional

Nissa Carrodus

Facility Lead at BASE, UQ | Consultant | Biopharmaceutics development | biologics formulation

Rachel Yoon Chang

Postdoctoral Bioinformatician

Magdalena Budzinska, PhD

mRNA Biology/mRNA Manufacturing/mRNA Delivery

Natasha Chaudhary, PhD

BASE Facility

The BASE mRNA Facility builds #mRNA #vaccines and #therapies for Australian researchers. We offer end-to-end services; from initial #design , #manufacture , and #formulation of mRNA. We have a successful track record of making hundreds of mRNA vaccines and therapies for a wide range of #applications . We are a team of passionate #scientists with expertise in mRNA #biology , #vaccine and #drug development, #biomanufacture and #clinical research. The BASE mRNA Facility is a non-profit facility supported by The University of Queensland and Therapeutic Innovation Australia and it is located at Australian Institute for Bioengineering and Nanotechnology AIBN . Our Services: 🔹 mRNA Design 🔹 mRNA Production (100ug to >5mg scale) 🔹 mRNA Formulation We understand that every research project is unique, which is why we offer two distinct options: 1️⃣ #Off -the-shelf #reporter #mRNA - Featuring a diverse selection, including eGFP, luciferase, nanoluc, mCherry, CRISPR Cas9, and ovalbumin, to name a few. 2️⃣ #Custom #mRNA #Production - Tailored to your precise specifications, this encompassing service includes: ✓ Optimization of sequences of interest ✓ Sequence synthesis and cloning into our BASE mRNA vector (which includes T7 promoter, optimised UTRs and polyA) ✓ Template Amplification and Purification for in vitro transcription (IVT) process. ✓ IVT and purification yielding capped or uncapped mRNA, with the option of unmodified or modified nucleotides, such as N1-Methylpseudouridine or Methoxyuridine. ✓ Comprehensive mRNA analysis and detailed reporting. Our Standard mRNA Production #Amounts : ✓ Small Scale: ~80-100ug ✓ Large Scale: ~1mg, ~2mg, ~5mg ✓ For quantities exceeding 5mg, we are delighted to discuss your specific requirements. Embark on your research journey with us! To initiate the process, simply click the link below to complete our #enquiryform . We are eager to learn more about your research goals and collaborate on groundbreaking scientific endeavors, driven by our cutting-edge mRNA solutions. 👉 [Enquiry Form Link]: https://lnkd.in/eWpHDK2E If you prefer direct communication, feel free to reach us via #email at base@uq.edu.au . #BASEmRNA #mRNAresearch #ScienceAdvancements #ResearchSolutions #Biotechnology #Genetics #mRNA #CustommRNA #AustraliaResearch #ScientificBreakthroughs #Innovation #ScienceCommunity #ResearchGoals

It seems like #mRNA vaccines have finally cracked the challenging Flu B strains, paving the way for widespread adoption. While earlier mRNA flu vaccines were highly effective against A strains their efficacy against B strains fell short. Now reconfigured vaccines from first Moderna and now GSK (partnered with CureVac ) have demonstrated non-inferiority to conventional flu vaccines. Given the scalability and rapid manufacture enabling rapid adaptation to seasonal strains, it's not hard to envision mRNA capturing a large section of Flu market in the near future. https://lnkd.in/gpt4ayMC

Seth Cheetham

A big congratulations to Muhammed B Sabdia who received the prestigious 2024 Gunn Family Haematology Fellowship from the Snowdome Foundation . 👏 Muhammed will develop personalised #mRNA vaccine in collaboration with BASE Facility to treat AL amyloidosis. Read more about Muhammed's project: https://lnkd.in/dYThTgvb

A-RNA 2024 Day 3! Dr Laura Leighton from BASE’s Research Team presented on the delivery of mRNA therapeutics in liver disease and cancer. Her talk was followed by an engaging QnA session, discussing about in vivo liver cancer model for testing mRNA therapeutics. The BASE team had a great time in Melbourne, enjoying all the discussions on mRNA design, our synthetic production approach, LNP formulation capabilities, potential new projects and collaborations, as well as great coffee ☕️. 🧬 Natasha Chaudhary, PhD Rachel Yoon Chang

We had a great start to the A-RNA Conference today in Melbourne. It is inspiring to see all the progress in the RNA research space across Australia and New Zealand. Drop by our table and connect with Rachel Yoon Chang and Natasha Chaudhary, PhD to discuss how we can help support your mRNA and LNP research. Also, stay tuned for Laura Leighton ’s talk on Wednesday!

We are excited to share our latest research in bioRxiv, introducing a novel method for targeted mRNA delivery. Bettina D. , Timothy Mercer and Seth Cheetham from BASE's Research Team used bispecific antibodies (BsAbs) to link mRNA-LNPs to specific cell surface markers in collaboration with James Humphries , Christopher Howard and Kristofer Thurecht . This technology has the potential to enable more precise and effective mRNA therapies. Key advantages: 💡 Innovative Delivery: BsAbs were used to target cell-surface proteins, retaining the original properties of the LNPs for better delivery. 💡 Targeted Action: Demonstrated effective, cell-type-specific targeting of EGFR and PSMA positive cells both in vitro and in vivo. 💡 Flexibility: This approach allows for easy adaptation by changing the cell-targeting region of the BsAbs, enabling rapid development of next-generation targeted mRNA drugs. Read more: https://lnkd.in/gDzUY7aV #mRNA #therapies #delivery #BispecificAntibodies #BsAbs #ResearchAndDevelopment Australian Institute for Bioengineering and Nanotechnology AIBN , Therapeutic Innovation Australia , UQ Centre for Advanced Imaging

We're hiring a senior research assistant to help drive our research ambitious programme in mRNA drug discovery. The position will work with a high-performing team at the Australian Institute for Bioengineering and Nanotechnology AIBN and BASE Facility to develop new mRNA candidates including individualised vaccines for cancer. Please share and apply below if this sounds like the role for you!

Join Timothy Mercer , as he discusses the biology, research and technologies of RNA modifications in this first seminar of the AMM Scientific and Technology Series

Looking forward to the A-RNA24 conference in Melbourne from October 21-23! 🌟 BASE is proud to sponsor this event, and we invite you to visit us at Table 14. Our Facility Lead, Rachel Yoon Chang , and Production Lead, Natasha Chaudhary, PhD , will be on hand to discuss how we can support your mRNA and LNP research needs. On 23rd Oct (Day 3), Laura Leighton from BASE Research Team will be presenting on 'Synthetic messenger RNA delivery in healthy liver, liver disease and cancer'. Also, don't forget to drop by our poster 'mRNA Design and Production: A Streamlined Approach to Accelerate Vaccine and Therapy Development' presented by Natasha . Come meet our team and learn more about our capabilities and services. We’re excited to engage with fellow researchers and explore new opportunities together. See you there! #mRNA #LNP #Research #Biotech

BASE Deputy Director Seth Cheetham along with Dr Jelle Van Den Ameele (Neurologist, University of Cambridge ) received a grant from The Lily Foundation to tackle the rare and fatal condition known as Mitochondrial Neuro-Gastro-Intestinal Encephalomyopathy (MNGIE). The project aims to develop and evaluate a pioneering mRNA-based gene therapy. Read more: https://lnkd.in/gud8ye3t #mRNA #GeneTherapy #MNGIE

Metric
Company Name	BASE mRNA facility	Base4 Biotechnology	Alnylam Pharmaceuticals, Inc.	Arrowhead Pharmaceuticals
Symbol			ALNY
MSH ID	AU:ORG:BASEFACILITY	BIO:BASE4	COM:ALNYLAM	COM:ARROWHEADPHARMA
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	AU	US	US	US
Stage				Post-IPO Debt
Employee Count			2.10K
Website	basefacility.org.au	base4.bio	alnylam.com	arrowheadpharma.com
LinkedIn	base-facility
Founders

Metric
Market Cap	32.60B
Enterprise Value
Monthly Web Traffic	55.97K	15.59K
Web Traffic Growth	0.89	0.03
Valuation
Raised Capital	900M	400M

Metric
Revenue			1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit			1.52B
EBITDA			-228.12M
Operating Income			-282.18M
Net Income			-440.24M
EPS			-3.52
Diluted EPS			-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.87
Operating Profit Margin			0.04
EBITDA Margin			-0.12
Net Profit Margin			-0.03
Return on Equity			1.67
Return on Assets			-0.02
Return on Capital Employed			0.03

ORG

AU:ORG:BASEFACILITY

BASE mRNA facility

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-42.10
P/B Ratio			-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			16.84
EV Multiple			326.32

Metric
Days Sales Outstanding			68.92
Days Payables Outstanding			97.72
Days Inventory Outstanding			128.53
Operating Cycle			187.09
Cash Conversion Cycle			104.98
Asset Turnover			0.58

Metric
Operating Cash Flow			104.16M
Free Cash Flow			41.95M
Cash Flow to Debt			0.15
Operating Cash Flow/Sales			0.16
Free Cash Flow Yield			-0.00

Metric
Cash & Equivalents			812.69M
Accounts Receivable			-87.94M
Inventory			89.15M
Goodwill
Debt to Capitalization			1.20
Debt to Assets			0.34
Current Ratio			3.14
Quick Ratio			3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.13
R&D to Revenue			0.58
SG&A to Revenue			0.35